Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a

Related Experiment Video

Updated: Jul 7, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Diletta Bianchini1, Akali Jayanth, Yu Jo Chua

  • 1Department of Medicine, Royal Marsden Hospital, Down's Road, Sutton, Surrey, SM2 5PT UK.

Clinical Colorectal Cancer
|February 19, 2008
PubMed

Insights

EGFR inhibitors effectively treat cancers but often cause skin toxicity. This review explores the presentation, management, and potential of this side effect as a marker for treatment effectiveness.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Aberrant human epidermal growth factor receptor (HER1/EGFR/ErbB1) signaling is common in solid tumors.
  • EGFR inhibitors (EGFRIs), including monoclonal antibodies and tyrosine kinase inhibitors, are key cancer therapies.
  • EGFRIs are generally well-tolerated but frequently cause dose-dependent skin toxicities.

Purpose of the Study:

  • To review the clinical presentation of EGFR inhibitor-related skin toxicity.
  • To summarize the predictive and prognostic value of this toxicity.
  • To outline management strategies for EGFR inhibitor-induced dermatologic adverse events.

Main Methods:

  • Literature review of studies on EGFRIs and associated skin toxicities.
  • Analysis of clinical data regarding the presentation and management of rash.
  • Evaluation of research investigating the link between skin toxicity and treatment outcomes.

Main Results:

  • EGFRIs are associated with specific, dose-dependent skin toxicities.
  • Skin toxicity can lead to treatment modifications (dose reduction/interruption).
  • A potential correlation exists between rash severity and treatment efficacy.

Conclusions:

  • Understanding EGFR inhibitor-related skin toxicity is crucial for patient management.
  • Skin toxicity may serve as a surrogate marker for treatment response.
  • Effective management strategies are needed to mitigate discomfort and maintain treatment adherence.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...